Erasca (ERAS) Capital Expenditures (2020 - 2026)
Erasca posted quarterly Capital Expenditures of $36000.0 for Q1 2026, down 56.63% year-on-year from $83000.0 in Q1 2025, and up 300.0% on a QoQ basis from $9000.0 in Q4 2025.
Erasca (ERAS) has 7 years of Capital Expenditures data on file, last reported at $36000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures fell 56.63% year-over-year to $36000.0; the trailing twelve-month figure through Mar 2026 stood at $81000.0 (down 19.8% YoY), and the FY2025 full-year result was $128000.0, up 113.33% from the prior year.
- Capital Expenditures for Q1 2026 stood at $36000.0, up from $9000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $7.3 million in Q1 2022 and bottomed at $5000.0 in Q3 2024.
- The 5-year median for Capital Expenditures is $82500.0 (2023), against an average of $1.0 million.
- The widest annual swing landed in 2022, when Capital Expenditures surged 5913.11%; it then sank 97.92% in 2024.
- A 5-year view of Capital Expenditures shows it stood at $864000.0 in 2022, then sank by 90.51% to $82000.0 in 2023, then plunged by 93.9% to $5000.0 in 2024, then jumped by 80.0% to $9000.0 in 2025, then surged by 300.0% to $36000.0 in 2026.
- The last three Capital Expenditures figures came in at $36000.0 (Q1 2026), $9000.0 (Q4 2025), and $6000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,000.00 |
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Dec 31, 2025 | 9,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 30,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Jun 30, 2024 | 13,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Dec 31, 2023 | 82,000.00 |
| Sep 30, 2023 | 240,000.00 |
| Sep 30, 2023 | 240,000.00 |
| Jun 30, 2023 | 247,000.00 |
| Jun 30, 2023 | 247,000.00 |
| Mar 31, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.21 Mn |
| Dec 31, 2022 | 864,000.00 |
| Dec 31, 2022 | 864,000.00 |
| Sep 30, 2022 | 1.79 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 4.56 Mn |
| Jun 30, 2022 | 4.56 Mn |
| Mar 31, 2022 | 7.34 Mn |
| Mar 31, 2022 | 7.34 Mn |
| Dec 31, 2021 | 5.83 Mn |
| Dec 31, 2021 | 5.83 Mn |
| Sep 30, 2021 | 4.67 Mn |
| Sep 30, 2021 | 4.67 Mn |
| Jun 30, 2021 | 579,000.00 |
| Jun 30, 2021 | 579,000.00 |
| Mar 31, 2021 | 122,000.00 |
| Mar 31, 2021 | 122,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 149,000.00 |
| Sep 30, 2020 | 149,000.00 |